An editorial in The Lancet Infectious Diseases discusses the adequacy of doxyPEP as an intervention for STI prevention.
“Whether authorities recommend doxyPEP, one could say that the horse has already bolted. Demand for it, and acceptance of it, are high. Rollout of effective vaccines that protect against bacterial STIs without driving AMR would be the best possible solution, but most candidates are in only the very early stages of clinical development… Ongoing studies should help settle the issue, but in the meantime the ease of purchase of doxycycline make regulation and surveillance of doxyPEP nigh on impossible.”
Source : The Lancet Infectious Diseases
Related HIV and Co-Infections News
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
-
EL PAÍS: US aid cuts collapse Malawi’s LGBTQ+ health services as volunteers scramble to fill the void
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.